Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

LLY's stock drops despite Q2 earnings beat, as its oral obesity pill underwhelms with 12.4% weight loss in trial.

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

The Times has amended a headline that incorrectly suggested doctors should monitor patients taking Ozempic injections in ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

The 2024 European clinical practice guidelines introduce a pivotal terminology shift, replacing NAFLD (non-alcoholic fatty liver disease) with MASLD (metabolic dysfunction-associated steatotic liver ...

Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...